The results of the CheckMate 9DW pivotal study, evaluating nivolumab plus ipilimumab as a first-line treatment for unresectable hepatocellular carcinoma, were published on 2025-01-01 in The Lancet. This open-label, randomized trial compared the combination therapy against lenvatinib or sorafenib.
Background
The study investigated nivolumab in combination with ipilimumab for participants with unresectable hepatocellular carcinoma (HCC). HCC is a primary liver cancer, and for patients with unresectable disease, effective first-line treatment options are crucial.
Trial design
The CheckMate 9DW study was an open-label, randomized trial. It evaluated nivolumab plus ipilimumab as a first-line treatment for patients with unresectable hepatocellular carcinoma. The experimental arm was compared against standard treatments, specifically lenvatinib or sorafenib.
What this means
The publication of the CheckMate 9DW trial results makes the full data on nivolumab plus ipilimumab for first-line unresectable hepatocellular carcinoma available to the scientific and medical community. This allows clinicians and researchers to review the detailed efficacy and safety outcomes of this combination therapy compared to lenvatinib or sorafenib. The findings from this pivotal study will inform treatment decisions and future research directions for patients with this challenging cancer.
Source
The information regarding this publication was sourced from PubMed, a database of biomedical literature. The results for the CheckMate 9DW study, titled "Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, rando", were published on 2025-01-01 in The Lancet and are accessible via pubmed.ncbi.nlm.nih.gov.